IUD

3Daughters Successfully Closes Over $2 million in First Tranche of Seed Financing Round

Retrieved on: 
Monday, January 22, 2024

MANSFIELD, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- 3Daughters , a clinical development company fueling evolutionary healthcare for women, announces closing of the first tranche in excess of $2 million in a Seed Round.

Key Points: 
  • MANSFIELD, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- 3Daughters , a clinical development company fueling evolutionary healthcare for women, announces closing of the first tranche in excess of $2 million in a Seed Round.
  • 3Daughters has a unique and frameless delivery platform, based on physics and geometry, for targeted therapy directly into the uterus.
  • 3D-001, a novel IUD containing copper, a proven spermicide for contraception, is the first product resulting from the technology.
  • This investment marks the next chapter for 3Daughters and allows us to execute our streamlined development plans to move into the clinic.

Danco Statement on Filing of Cert Petition, September 8, 2023

Retrieved on: 
Friday, September 8, 2023

Danco remains confident in the safety and effectiveness of Mifeprex® under the 2023 REMS that currently governs its use.

Key Points: 
  • Danco remains confident in the safety and effectiveness of Mifeprex® under the 2023 REMS that currently governs its use.
  • The changes in 2016 and 2021—approved by FDA after careful analysis—have expanded the availability and use of Mifeprex®, providing crucial individual and public health benefits.
  • Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following MIFEPREX use.
  • The frequency of adverse reactions varies between studies and may be dependent on many factors including the patient population and gestational age.

Emergency contraception: here’s what you probably don’t know but should

Retrieved on: 
Thursday, August 31, 2023

Whatever the reason, if you need to prevent an unplanned pregnancy you might decide to use emergency contraception.

Key Points: 
  • Whatever the reason, if you need to prevent an unplanned pregnancy you might decide to use emergency contraception.
  • For emergency IUD fittings, you need to go to a contraceptive and sexual health clinic, or your GP or gynaecologist.
  • This article is part of Quarter Life, a series about issues affecting those of us in our twenties and thirties.

How does it work?

    • Levonorgestrel and ulipristal both work by delaying ovulation.
    • This means that if there are sperm inside the fallopian tubes, there won’t be an egg for them to meet and fertilise.
    • In a typical menstrual cycle, you’re most at risk of pregnancy on days nine to 14.
    • But even if you’re more than halfway through your typical monthly cycle, these tablets can still work.

How effective is it?

    • While it’s the most effective form of emergency contraception, it can be uncomfortable or even painful to have an IUD fitted.
    • It’s at least 95% effective at stopping pregnancies when taken within this time frame.
    • Levonorgestrel is 95% effective at preventing pregnancy if taken within 24 hours of unprotected sex.
    • But both tablets are up to 95% effective at stopping pregnancies when taken soon after unprotected sex.

What should you expect?

    • It may also cause your next period to begin earlier or later than normal.
    • Ectopic pregnancy (when a fertilised egg implants in a fallopian tube) may be possible if emergency contraception fails.
    • It’s also worth noting that emergency contraceptives have no effect on long-term fertility and can be used even if you plan to have children later on.

Danco Statement on 5th Circuit Ruling, August 16, 2023

Retrieved on: 
Thursday, August 17, 2023

NEW YORK, Aug. 16, 2023 /PRNewswire/ -- The Fifth Circuit panel's decision is inconsistent with established Supreme Court principles governing standing and administrative law challenges.

Key Points: 
  • NEW YORK, Aug. 16, 2023 /PRNewswire/ -- The Fifth Circuit panel's decision is inconsistent with established Supreme Court principles governing standing and administrative law challenges.
  • Danco remains confident in the safety and effectiveness of Mifeprex® and committed to making the drug available as broadly as possible.
  • Danco will continue to be at the forefront of this fight, working closely with the reproductive rights community and pharmaceutical industry, as this case moves forward.
  • Over 5 million women have used Mifeprex® in the United States since its approval for the termination of early pregnancy in 2000.

Curae Pharma360 Promotes Autumn Ehnow to Chief Executive Officer

Retrieved on: 
Tuesday, June 13, 2023

SAN FRANCISCO, June 13, 2023 /PRNewswire/ -- Curae Pharma360 (Curae), a mission-driven pharmaceutical company strengthening access to and affordability of life-changing generic medicines, announced today it has promoted Autumn Ehnow to Chief Executive Officer. A founding leader of Curae and its Chief Operating Officer since the company's inception last year, Ehnow will continue to serve as Executive Vice President, Policy & Strategic Market Access at Medicines360, the nonprofit parent company of Curae.

Key Points: 
  • Ehnow's Leadership and Operational Expertise to Drive Curae's Growth, Partnerships, and Product Portfolio
    SAN FRANCISCO, June 13, 2023 /PRNewswire/ -- Curae Pharma360 (Curae), a mission-driven pharmaceutical company strengthening access to and affordability of life-changing generic medicines, announced today it has promoted Autumn Ehnow to Chief Executive Officer.
  • A founding leader of Curae and its Chief Operating Officer since the company's inception last year, Ehnow will continue to serve as Executive Vice President, Policy & Strategic Market Access at Medicines360, the nonprofit parent company of Curae.
  • Ehnow, who had a major role establishing the commercial operations at Curae, brings two decades of experience as a pharmaceutical and nonprofit leader to the CEO role.
  • "Autumn's expertise is exactly what Curae needs in a leader," said Andrea Olariu, MD, PhD, CEO of Medicines360.

Want long-term contraception? There are more effective options than the pill. But they can be hard to find

Retrieved on: 
Thursday, June 1, 2023

Australians’ access to a range of contraceptive options depends on where they live and how wealthy they are.

Key Points: 
  • Australians’ access to a range of contraceptive options depends on where they live and how wealthy they are.
  • A recent parliamentary inquiry recommends ways to end this “postcode lottery” for people who want to use long-acting reversible contraception.
  • There are several types of long-acting reversible contraception: the hormonal contraceptive implant, the hormonal intrauterine devices (IUD) and copper IUDs.

How do they work?

    • It releases a progestogen hormone which prevents monthly egg release from the ovary for up to three years.
    • IUDs are small T-shaped devices which are inserted into the uterus.
    • Hormonal IUDs contain a progestogen hormone and mainly work by thickening the cervical mucus and preventing sperm from swimming up into the uterus.

They have additional benefits for some users

    • As well as better protection from pregnancy, some long-acting reversible contraception methods have other benefits.
    • The hormonal IUD, Mirena, for example, reduces heavy menstrual bleeding.
    • This includes people with hormone-driven cancers such as breast cancer, for whom any hormonal contraceptive would be considered unsafe.

Why aren’t they more available?

    • Out-of-pocket IUD insertion-related costs can also vary from zero to hundreds of dollars if people don’t have access to publicly funded services.
    • Here’s what to expect

      On the supply side, too few health professionals provide these essential services.

    • There are multiple successful models of nurse-led long-acting reversible contraception services and postpartum insertion of implants by midwifes nationally and internationally.
    • However, most nurses aren’t able to access Medicare remuneration, which creates additional barriers for this highly skilled workforce to provide these services.

What are the recommendations for reform?

    • The Senate inquiry has recognised these barriers and recommends making contraception universally affordable, and specifically, subsidising copper IUDs.
    • It also recommends adequate remuneration through Medicare for GPs, nurses and midwives to provide long-acting reversible contraception insertion and removal, and collaborative efforts between the government and medical colleges to improve access to workforce training.
    • While the recommendations are welcome, they now need to be turned into actions through adequate funding.

Medicines360 Appoints Andrea Olariu, MD, PhD as Chief Executive Officer

Retrieved on: 
Tuesday, May 30, 2023

SAN FRANCISCO, May 30, 2023 /PRNewswire/ -- Medicines360, a mission-driven nonprofit women's health pharmaceutical organization, announced today that its Board of Directors has named Andrea Olariu, MD, PhD as Chief Executive Officer, effective immediately. Dr. Olariu served most recently as Chief Operating Officer (COO) for Medicines360 and succeeds Tina Raine-Bennett, MD, MPH, FACOG.

Key Points: 
  • Dr. Olariu brings depth of expertise in Clinical, Medical and Regulatory Affairs, and Product Development
    SAN FRANCISCO, May 30, 2023 /PRNewswire/ -- Medicines360, a mission-driven nonprofit women's health pharmaceutical organization, announced today that its Board of Directors has named Andrea Olariu, MD, PhD as Chief Executive Officer, effective immediately.
  • Dr. Olariu served most recently as Chief Operating Officer (COO) for Medicines360 and succeeds Tina Raine-Bennett, MD, MPH, FACOG.
  • "Dr. Olariu assumes leadership at an exciting time for Medicines360," said Leslie Benet, PhD, Professor of Bioengineering and Therapeutic Sciences and Pharmaceutical Chemistry at the University of California, San Francisco, and Medicines360 Board Chair.
  • As COO of Medicines360, Dr. Olariu oversaw Clinical/Medical and Regulatory Affairs, Product Development, and the Quality Department; and served as Chief Executive Officer of its for-profit subsidiary, CuraePharma360.

Bayer launches Seeing Red campaign around the treatment of Heavy Menstrual Bleeding (HMB)

Retrieved on: 
Tuesday, May 16, 2023

Seeing Red encourages women across America to talk to their healthcare provider about their heavy periods and discuss if Mirena could be right for them.

Key Points: 
  • Seeing Red encourages women across America to talk to their healthcare provider about their heavy periods and discuss if Mirena could be right for them.
  • Symptoms may include needing to double up on pads or having to change pads or tampons during the night.
  • Through our Seeing Red campaign, we want to elevate the importance of effective contraception and a potential treatment option for heavy menstrual bleeding.”
    The Seeing Red campaign is a national, multi-channel media campaign featuring a commercial shedding light on a contraceptive and HMB treatment option, partnerships with healthcare provider and patient influencers, and social and digital content with Betches Media.
  • To learn more about the campaign and about a birth control that may also help with HMB, visit Mirena.com .

ADAMEVE.COM ASKS "DO YOU BELIEVE THERE SHOULD BE AGE RESTRICTIONS FOR CONTRACEPTIVES?"

Retrieved on: 
Thursday, May 11, 2023

This month, the company surveyed over 1000 people, asking "Do you believe there should be age restrictions for contraceptives?"

Key Points: 
  • This month, the company surveyed over 1000 people, asking "Do you believe there should be age restrictions for contraceptives?"
  • "The issue here is these numbers are ever-changing," says Dr. Jenni Skyler, PhD, LMFT, CST, and resident sexologist at Adam & Eve.
  • "With fears that birth control restrictions could follow abortion bans, Americans are rightly concerned about reproductive rights.
  • For additional information on Adam & Eve, please contact Adam & Eve Director of Public Relations Katy Zvolerin at 919.644.8100 x 3121 or [email protected] .

SCOTUS Issues Stay

Retrieved on: 
Saturday, April 22, 2023

NEW YORK, April 21, 2023 /PRNewswire/ -- We at Danco are gratified the Supreme Court has granted a stay, which keeps the approval of Mifeprex intact without any changes. This stay is an important step in maintaining access to medication abortion during the litigation. Danco stands by the well-established safety profile of Mifeprex and FDA's repeated and careful review of the data and literature in approving the drug and modifying the conditions under which it is available. We remain committed to working with healthcare providers, patients and state and federal governments to keep Mifeprex available and accessible.

Key Points: 
  • This stay is an important step in maintaining access to medication abortion during the litigation.
  • Danco: Gratified the Supreme Court has granted a stay, which keeps the approval of Mifeprex intact without changes.
  • Over 5 million women have used Mifeprex® in the United States since its approval for the termination of early pregnancy in 2000.
  • Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following MIFEPREX use.